Baccalini Edoardo Andrea, Renne Salvatore Lorenzo, Colombo Piergiuseppe, Pasqualini Fabio, Quagliuolo Vittorio Lorenzo, Cananzi Ferdinando Carlo Maria, Grizzi Fabio, Borroni Elena Monica
Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy.
Department of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy.
Anticancer Agents Med Chem. 2023;23(20):2248-2253. doi: 10.2174/1871520623666230207091429.
Desmoid tumors have an extremely variable natural history. The uncertainty behind desmoid behavior reflects the complexity, which subtends its development and non-linear advancement. Apart from Wnt- βcatenin mutation, estrogen receptors, and COX-2 overexpression, little is known about the ability of desmoids to grow and recur while being unable to metastasize. Several tumors have been shown to express the CXCR4/CXCR7/CXCL12 axis, whose functions are essential for tumoral development.
This study aimed to investigate the expression of the CXCR4/CXCR7/CXCL12 axis in primary desmoid tumors and discuss the potential role of this key-signaling as an antiangiogenic therapeutic strategy.
In this study, 3 μm-thick consecutive sections from each formalin-fixed and paraffin-embedded tissue block were treated with mouse monoclonal antibodies developed against CD34, CXCR4, CXCR7, and CXCL12.
Two distinct vessel populations: CXCR4 and CXCR4- vessels, have been found. Similarly, chemokine receptor CXCR7 expression in the entire desmoid tumor series positively stained a portion of tumor-associated vessels, identifying two distinct subpopulations of vessels: CXCR7 and CXCR7- vessels. All 8 neoplastic tissue samples expressed CXCL12. Immunohistochemical positivity was identified in both stromal and endothelial vascular cells. Compared to CXCR4 and CXCR7, the vast majority of tumor-associated vessels were found to express this chemokine.
It is the first time, as per our knowledge, that CXCR4/CXCR7/CXCL12 axis expression has been identified in a desmoid type-fibromatosis series. CXCL12 expression by neoplastic cells, together with CXCR4 and CXCR7 expression by a subgroup of tumor-associated vessels, was detected in all desmoid tumor tissue samples examined. Since chemokines are known contributors to neovascularization, CXCR4/CXCR7/CXCL12 axis may play a role in angiogenesis in this soft-tissue tumor histotype, thereby supporting its growth.
硬纤维瘤具有极其多变的自然病程。硬纤维瘤行为背后的不确定性反映了其发展和非线性进展的复杂性。除了Wnt-β连环蛋白突变、雌激素受体和COX-2过表达外,对于硬纤维瘤在无法转移的情况下生长和复发的能力知之甚少。已有研究表明,几种肿瘤表达CXCR4/CXCR7/CXCL12轴,其功能对肿瘤发展至关重要。
本研究旨在调查原发性硬纤维瘤中CXCR4/CXCR7/CXCL12轴的表达情况,并探讨这一关键信号作为抗血管生成治疗策略的潜在作用。
在本研究中,将每个福尔马林固定、石蜡包埋组织块的连续3μm厚切片用针对CD34、CXCR4、CXCR7和CXCL12研制的小鼠单克隆抗体进行处理。
发现了两种不同的血管群体:CXCR4血管和CXCR4阴性血管。同样,在整个硬纤维瘤系列中,趋化因子受体CXCR7的表达使一部分肿瘤相关血管呈阳性染色,识别出两种不同的血管亚群:CXCR7血管和CXCR7阴性血管。所有8个肿瘤组织样本均表达CXCL12。在基质和内皮血管细胞中均鉴定出免疫组化阳性。与CXCR4和CXCR7相比,发现绝大多数肿瘤相关血管表达这种趋化因子。
据我们所知,这是首次在硬纤维瘤型纤维瘤病系列中鉴定出CXCR4/CXCR7/CXCL12轴的表达。在所有检测的硬纤维瘤组织样本中均检测到肿瘤细胞表达CXCL12,以及肿瘤相关血管亚群表达CXCR4和CXCR7。由于趋化因子是已知的新血管形成的促成因素,CXCR4/CXCR7/CXCL12轴可能在这种软组织肿瘤组织类型的血管生成中发挥作用,从而支持其生长。